Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000019617-25-000501
Filing Date
2025-06-05
Accepted
2025-06-05 13:42:44
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4870
  Complete submission text file 0000019617-25-000501.txt   7014
Mailing Address 383 MADISON AVENUE NEW YORK NY 10017
Business Address 383 MADISON AVENUE NEW YORK NY 10017 2122706000
JPMORGAN CHASE & CO (Filed by) CIK: 0000019617 (see all company filings)

EIN.: 132624428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Subject) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87380 | Film No.: 251026541
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)